Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.62 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.62 |
| ▸ | AKT1 | P31749 | 3/20 | 0.62 |
| ▸ | GSK3B | P49841 | 3/20 | 0.62 |
| ▸ | NEK4 | P51957 | 3/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.62 |
| ▸ | PRKG2 | Q13237 | 3/20 | 0.62 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.62 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.62 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.62 |
| ▸ | PRKCG | P05129 | 2/20 | 0.62 |
| ▸ | CDK1 | P06493 | 2/20 | 0.62 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.62 |
| ▸ | CDK2 | P24941 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | AKT2 | P31751 | 2/20 | 0.62 |
| ▸ | GSK3A | P49840 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5867888 | 1.00 | ROCK1 (0.62) | ROCK1ROCK2RPS6KA5AKT1GSK3B | |
| SCHEMBL9848486 | 0.85 | RPS6KA5 (0.71) | ROCK1ROCK2RPS6KA5AKT1GSK3B | |
| SCHEMBL3104277 | 0.82 | ROCK2 (0.78) | ROCK1ROCK2RPS6KA5AKT1GSK3B | |
| SCHEMBL28476592 | 0.81 | ALDH1A1 (0.86) | ALDH1A1CYP3A4GAANPC1RAB9A | |
| SCHEMBL6214070 | 0.81 | UTS2R (0.57) | ALDH1A1CYP3A4GAANPC1UTS2R | |
| SCHEMBL6214067 | 0.81 | UTS2R (0.57) | ALDH1A1CYP3A4GAANPC1UTS2R | |
| SCHEMBL6215659 | 0.80 | ALDH1A1 (0.60) | ALDH1A1CYP3A4GAANPC1RAB9A | |
| SCHEMBL6213961 | 0.80 | ALDH1A1 (0.60) | ALDH1A1CYP3A4GAANPC1RAB9A | |
| SCHEMBL5927045 | 0.79 | ALDH1A1 (0.69) | ALDH1A1CYP3A4GAANPC1RAB9A | |
| SCHEMBL6369720 | 0.79 | RAB9A (0.57) | MAPK1ALDH1A1CYP3A4GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053078-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1289954-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1192132-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6900196-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-6855715-B1 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | LIEBESCHUETZ JOHN WALTER (GB) | 2005-02-10 | — | — | US | disclosed |
| US-20040259868-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-23 | — | — | US | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-1289954-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192132-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076971-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | ROCK1 2392/4885ROCK2 2919/4885RPS6KA5 2208/4885 |
| US-20040259868-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | ROCK1 1459/4885ROCK2 2690/4885RPS6KA5 3386/4885 |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | SERPINB1, SERPINE1, SERPINH1 | ROCK1 3325/4885ROCK2 3753/4885RPS6KA5 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.